Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oncolytic Virotherapy Mitigates the Selection of IFN-Resistant Tumor Cells Following Immunotherapy, Yet Faces Challenges from the Rise of Dedifferentiated Tumor Cells

  • By

  • Susan Gellert

  • Bastian Kruse

  • Johannes Peters

  • Susanne Bonifatius

  • Thomas Tüting

  • Anthony C. Buzzai

  • June 22, 2026

Share

Original Source(s)

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells

  • by Susan Gellert, Bastian Kruse, Johannes Peters, Susanne Bonifatius, Thomas Tüting, Anthony C. Buzzai

  • June 22, 2026

Related Content

New Podcast Feature: Dr. Geoffrey Young on SurgOnc Today

Join Baptist Health's Dr. Geoffrey Young as he joins Drs. Sonia Cohen and Ashley Holder on the latest episode of SurgOnc Today.

  • by

  • August 28, 2026

  • 1 min
Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.